Hannah Clarke

Adding niraparib to abiraterone acetate and prednisone (AAP) was associated with an overall survival benefit compared with AAP alone in patients with BRCA1/2-mutated metastatic castration-resistant prostate cancer.

Data from the study showed a median PSA-PFS of 13 months with the combination therapy compared with 7.8 months with enzalutamide alone.

Data showed noninferiority of subcutaneous nivolumab to intravenous nivolumab in the time-average to nivolumab serum concentration over 28 days (Cavgd28) and the trough serum concentration at steady state (Cminss).

"Our data show no evidence of benefit from selenium and evidence of harm from vitamin E—a compound readily available over the counter," the authors write.

The model may help identify patients with urothelial carcinoma who could benefit from PPARG inhibition through FX-909, a first-in-class small molecule inhibitor of PPARG.

Overall, 43.3% of patients who had received a diagnosis of NMIBC had 1 or more additional lesions detected with APL-1706 plus BLC compared with WLC alone.

“The ClarityDX Prostate test will reduce the number of unnecessary prostate biopsies, which are invasive, uncomfortable, and carry some risk,” says John D. Lewis, PhD.

Preliminary findings from the study showed a decrease in PSA levels across all doses of PDS0301 assessed.

In this installment, Christopher E. Ramsey, MD, FACS, and Rachel Vann, MSN, RN, NP-C, highlight Tennessee Urology, an affiliate of United Urology Group.

“These findings demonstrate that electrofulguration provides a durable clinical cure that enables many postmenopausal women to remain UTI-free with minimal to no continued need for antibiotic therapy," says Philippe E. Zimmern, MD.

At 3 months following treatment, 50% of men who received CCH injections reported being “very satisfied” overall, compared with 21% of patients in the surgery group.

In patients with microhematuria, a positive result on the test was associated with a 5-fold increase in the risk of patients harboring bladder cancer compared with current metrics alone.

"If additional research confirms our findings, this may lead to a new paradigm in the treatment of muscle-invasive bladder cancer," says Matthew Galsky, MD.

"I treat all aspects of male and female incontinence, whether this be artificial urinary sphincter, the male sling, female sling, bladder Botox, or sacral neuromodulation," said Jas Singh, MD, FRCS.

The study achieved 100% local control and cancer-specific mortality rates with stereotactic ablative body radiotherapy.

"Psychological factors often have an important role [in erectile dysfunction], and psychological treatment options are available that have been found to improve outcomes," said Mark S. Allen, PhD.

"Results showed that more than two-thirds of these men were found to have positive Posluma scans, with a quarter of them having extrapelvic lesions," says Ashesh B. Jani, MD, MSEE, FASTRO.

Data showed that the proportion of Black patients referred for genomic testing increased from 19% to 58% after the implementation of the precision medicine navigator.

The approval is supported by findings from the phase 2 PHYOX2 trial and interim data from the phase 3 PHYOX3 extension study.

Patients who underwent treatment with SBRT demonstrated a 5-year disease control rate of 96%, compared with 95% among patients who underwent conventionally fractionated radiation therapy.

The positioning system would allow patients with cancer to undergo radiation therapy in an upright, seated position.

The inclusion of iTind is reflected in a newly added statement on temporary implanted prostatic devices.

The findings suggest that drug therapies targeting the NOTCH1 gene may serve as an alternative treatment option for patients with kidney cancer in whom surgery is not recommended.

The PSE test was shown to improve the predictive accuracy of a standard PSA test from 55% to 94%.

The reimbursement code for flotufolastat F 18 will be effective October 1, 2023.

“[These] results imply that prostate cancer survival could be improved, especially in historically under-served groups, by improving the timeliness of access to medical care," says Sean Clouston, PhD.

“The ADVANCED-2 trial in NMIBC is an exciting opportunity to build on the favorable anti-tumor and safety data of TARA-002 presented earlier this year," says Gautam Jayram, MD.

Patients with mCRPC will be randomly assigned 2:1 to receive masofaniten/enzalutamide or enzalutamide alone.

The supplemental new drug application is supported by findings from the LITESPARK-005 trial.

In total, the prospective SOPHIA study enrolled 6 men with stress urinary incontinence who have reduced outlet resistance due to intrinsic sphincter deficiency.